Search Results

You are looking at 141 - 150 of 793 items for :

  • "screening" x
Clear All
Full access

Johan Maertens, Kristel Buvé and Elias Anaissie

Infect Dis 2004 ; 4 : 349 – 357 . 11. Maertens J Verhaegen J Lagrou K . Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation

Full access

Sierra Cheng, Matthew C. Cheung, Di Maria Jiang, Erica McDonald, Vanessa S. Arciero, Doreen Anuli Ezeife, Amanda Rahmadian, Alexandra Chambers, Kelley-Anne Sabarre, Ambika Parmar and Kelvin K.W. Chan

scoring. Of these 127 RCTs, 108 RCTs comprising 116 treatment comparisons reported HR OS and were therefore included in the primary analysis. Key characteristics of the included RCTs are described in Table 1 . Figure 1. Process of screening and scoring

Full access

Laurence Klotz

findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004 ; 64 : 544 – 550 . 18. Choo R DeBoer G Klotz L . PSA doubling time of prostate carcinoma managed with watchful observation alone

Full access

Alexander P. Cole, Chang Lu, Marieke J. Krimphove, Julie Szymaniak, Maxine Sun, Sean A. Fletcher, Stuart R. Lipsitz, Brandon A. Mahal, Paul L. Nguyen, Toni K. Choueiri, Adam S. Kibel, Adil H. Haider and Quoc-Dien Trinh

Background Insurance coverage impacts many aspects of cancer care, from screening 1 , 2 to treatment. 3 – 5 Insurance may also affect long-term outcomes, such as cancer progression and mortality. 6 , 7 The relative benefit may vary depending on

Full access

David E. Misek, Tasneem H. Patwa, David M. Lubman and Diane M. Simeone

treatments for women with breast cancer: outcome with relation to screening for the disease . Ann Oncol 2003 ; 14 : 1212 – 1214 . 12. Lieberman D . How to screen for colon cancer . Annu Rev Med 1998 ; 49 : 163 – 172 . 13. Ferguson

Full access

NCCN Guidelines Insights: Survivorship, Version 2.2019

Featured Updates to the NCCN Guidelines

Tara Sanft, Crystal S. Denlinger, Saro Armenian, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Divya Koura, Robin M. Lally, Terry S. Langbaum, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C.F. Moore, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Lindsay Peterson, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Phyllis Zee, Nicole R. McMillian and Deborah A. Freedman-Cass

years with a terminal diagnosis and uncertainty about the future; how to handle comorbid conditions and disease prevention, screening, and treatment in the setting of limited life expectancy; managing discussions regarding new drugs and early

Full access

Guadalupe R. Palos, Katherine Gilmore, Patricia Chapman, Weiqi Bi, Paula Lewis-Patterson and Alma Maria Rodriguez

Background: NCCN Guidelines recommend annual mammography for surveillance in asymptomatic women diagnosed with breast cancer. There is limited evidence to support which type of mammogram—screening or diagnostic—should be ordered for asymptomatic

Full access

Ann M. Berger, Kathi Mooney, Amy Alvarez-Perez, William S. Breitbart, Kristen M. Carpenter, David Cella, Charles Cleeland, Efrat Dotan, Mario A. Eisenberger, Carmen P. Escalante, Paul B. Jacobsen, Catherine Jankowski, Thomas LeBlanc, Jennifer A. Ligibel, Elizabeth Trice Loggers, Belinda Mandrell, Barbara A. Murphy, Oxana Palesh, William F. Pirl, Steven C. Plaxe, Michelle B. Riba, Hope S. Rugo, Carolina Salvador, Lynne I. Wagner, Nina D. Wagner-Johnston, Finly J. Zachariah, Mary Anne Bergman and Courtney Smith

clinically indicated. Screening should identify fatigue. Patients and families should be informed that managing fatigue is an integral part of total health care. All patients should receive symptom management. Furthermore, if patients cannot tolerate their

Full access

Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Shrujal Baxi, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Elizabeth Kvale, Robin M. Lally, Terry S. Langbaum, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Deborah A. Freedman-Cass and Nicole R. McMillian

Survivors for whom screening does not indicate an issue with sexual function should be rescreened at subsequent visits. For survivors with sexual function concerns who do not wish to discuss them at the current visit, referral can be made to a sexual health

Full access

Shilpa Grover and Sapna Syngal

particularly valuable given that genetic testing has limitations in sensitivity and that uninformative results may lead to false reassurance and poor adherence to recommended cancer screening. 42 Studies have shown that these 3 prediction models have